The only malignancy screening test among gynecological cancers is cervical cancer.

Cytology examination and Hpv typing with smear are used as screening tests. Hpv positivity is detected in more than 90% of cervical cancers. However, only the Hpv 16-18 type positive patients undergo colposcopy in the routine screening program.

Patients with Smear negative, Type 16-18 high-risk Hpv positivity are evaluated by quota after 1 year.

the authors performed colposcopy with this study; authors aimed to compare the results of patients with type 16-18 Hpv positivity and type 16-18 high-risk Hpv positivity and to find out whether there was any difference between them.

In this way, other high-risk Hpv types other than type 16-18 (31,33,35,45,51, etc.) may be exposed to premalign cervical lesions and possible cancer in a number of earlier and earlier periods by performing colposcopic examination instead of expecting to perform quota after 1 year. we aimed to remove.

Inclusion Criteria:

• 20-65 years old
• patients with normal smear

Exclusion Criteria:

• Patients with invasive cervical cancer,
• HIV-positive patients,
• ASCUS and more risky premalignant lesions in cytology,
• Over the age of 65 and
• Patients under 20 years of age,
• patients with another known gynecological malignancy

Patients with high-risk HPV and colposcopy were the study groups.